|
Fluidic Analytics – Understand the Machinery of Life
Proteins are the building blocks of life. They form the structure of cells, regulate cellular activity and carry out the biochemical processes that underpin function in every living organism. Just as DNA tells us what could happen over lifetimes, proteins and their behaviour tell us what is happening now.
Fluidic Analytics envisions a world where information about proteins and their behaviour transforms our understanding of how the biological world operates, and helps all of us make better decisions about how we diagnose diseases, develop treatments and maintain our personal well-being.
By building the world’s best tools, software and services for protein characterisation and making them universally accessible in the lab, in the clinic or at home, we are making this vision a reality not just for a small group of expert users, but for everyone who can benefit.
Fluidic Analytics are based in Cambridge and interested in talking to partners looking for novel tools to identify protein biomarkers, or who would like to explore new ways of optimising and monitoring protein purification, analysis and formulation.
To find out more about Fluidic Analytics, visit their website here »
|
|
Pelago Bioscience AB was founded in 2013 to develop and provide services based on the patented Cellular Thermal Shift Assay (CETSA). This assay is uniquely able to measure drug-target interactions in-situ within the cellular environment and can be applied against a specified protein target for compound screening and lead optimization (CETSA Classics and CETSA HT) or in a non-targeted proteomics study (CETSA Mass Spec). Critically CETSA require no modification to the ligand or target as it utilizes the natural thermodynamic properties of the protein itself and can be applied to any cell or sample type. CETSA MS is ideal for un-biased proteomics studies and is now used routinely for determining compound liabilities and for mode of action studies. A recent development has been the use of it to identify novel biomarkers. Pelago works exclusively on CETSA and is able to offer full assay development and screening services to its customers, using its own dedicated laboratories in Sweden.
To find out more about Pelago Bioscience AB, visit their website here »
Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology company, focusing on the research and development of disease modifying therapeutics candidates for Alzheimer’s disease (AD), Parkinson’s disease (PD) and other related neurodegenerative diseases.
Through its proprietary drug discovery programs Cantabio is
targeting the reduction of protein aggregation, oxidative and glyoxal stress, which are believed to be some of the main causes of AD and PD. Cantabio is currently developing small molecule pharmacological chaperones as drug candidates for clinical trials using an innovative therapeutic development approach. Cantabio focuses on three main protein targets and has four distinct therapeutic programs.
Cantabio’s strong management team has extensive experience in key strategic areas and has assembled a world-renowned scientific advisory board. The company has operations in Silicon Valley (USA), Cambridge (UK) and Budapest (Hungary), where multidisciplinary in-house R&D is carried out in our laboratory facility. Cantabio also has strong academic links with a number of academic institutions including the University of Cambridge and Purdue University, allowing cutting edge academic research support to Cantabio’s therapeutic programs.
To find out more about Cantabio Pharmaceuticals Inc, visit their website here »
At Cambridge Enplas Life science Lab (C.E.L.L), a subsidiary of Enplas Corporation, we are working on innovative research in the life science market.
Enplas decided to take a step forward in the life science market 17 years ago to answer the needs for microfluidic chips in the diagnostic market, by applying its core technology. With the creation of CELL, we are looking to apply this expertise to bring new innovations to the biotechnology market.
CELL as a lab is working on biotechnology applications such as organ on a chip, single cell, droplet microfluidics for the life science industry (pharmaceutical, cosmetic, food testing, environment). In addition, we are seeking new innovations where we can provide financial investment, management expertise, engineering support and global quality supply support.
Enplas is also able to transform your ideas into a mass production chip using our expertise and global facilities.
To find out more about Enplas, visit their website here »
|
